We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Respiratory Medicine

Journal Scan / Research · January 12, 2021

Onset of Effect and Impact on Severe Eosinophilic Asthma Treated With Benralizumab

The Lancet Respiratory Medicine


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Respiratory Medicine
Onset of Effect and Impact on Health-Related Quality of Life, Exacerbation Rate, Lung Function, and Nasal Polyposis Symptoms for Patients With Severe Eosinophilic Asthma Treated With Benralizumab (ANDHI): A Randomised, Controlled, Phase 3b Trial
Lancet Respir Med 2020 Dec 22;[EPub Ahead of Print], TW Harrison, P Chanez, F Menzella, GW Canonica, R Louis, BG Cosio, NL Lugogo, A Mohan, A Burden, L McDermott, E Garcia Gil, JG Zangrilli

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading